These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
748 related articles for article (PubMed ID: 22422823)
21. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981 [TBL] [Abstract][Full Text] [Related]
22. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542 [TBL] [Abstract][Full Text] [Related]
23. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma. Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305 [No Abstract] [Full Text] [Related]
24. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206 [TBL] [Abstract][Full Text] [Related]
25. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272 [TBL] [Abstract][Full Text] [Related]
28. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M; Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405 [TBL] [Abstract][Full Text] [Related]
29. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337 [TBL] [Abstract][Full Text] [Related]
30. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398 [TBL] [Abstract][Full Text] [Related]
31. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials. Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306 [TBL] [Abstract][Full Text] [Related]
32. Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. Saboo SS; Fennessy F; Benajiba L; Laubach J; Anderson KC; Richardson PG J Clin Oncol; 2012 Jul; 30(20):e175-9. PubMed ID: 22689802 [No Abstract] [Full Text] [Related]
33. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Kropff M; Liebisch P; Knop S; Weisel K; Wand H; Gann CN; Berdel WE; Einsele H; Ann Hematol; 2009 Nov; 88(11):1125-30. PubMed ID: 19274460 [TBL] [Abstract][Full Text] [Related]
34. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329 [TBL] [Abstract][Full Text] [Related]
35. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J; Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289 [TBL] [Abstract][Full Text] [Related]
36. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103 [TBL] [Abstract][Full Text] [Related]
37. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Lacy MQ; Allred JB; Gertz MA; Hayman SR; Short KD; Buadi F; Dispenzieri A; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Zeldenrust S; Fonseca R; Bergsagel PL; Roy V; Stewart AK; Laumann K; Mandrekar SJ; Reeder C; Rajkumar SV; Mikhael JR Blood; 2011 Sep; 118(11):2970-5. PubMed ID: 21690557 [TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ; Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192 [TBL] [Abstract][Full Text] [Related]
39. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660 [TBL] [Abstract][Full Text] [Related]
40. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]